Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia

Annals of Anatomy

Volumn 190, Issue 5, 2008, Pages 477-489

  Tripathi, Richa ^a   Rath, Gayatri ^a   Jain, Anju ^b   Salhan, Sudha ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

ELISA; Immunohistochemistry; Membranous VEGFR 1; Placenta; Pre eclampsia; sVEGFR1

Indexed keywords

VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOTROPHOBLAST; DISEASE MARKER; EARLY DIAGNOSIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SYNCYTIOTROPHOBLAST; UPREGULATION;

EID: 55149097472     PISSN: 09409602     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aanat.2008.08.002     Document Type: Article

References (63)

1. Ahmed A., Dunk C., Ahmad S., and Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen - a review. Placenta 21 (2000) S16-S24
2. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., and Smith L.E. Suppression of retinal neovascularization in vivo by inhibition of VEGF using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92 (1995) 457-461
3. Autiero M., Lutton A., Tjwa M., and Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemostasis 1 (2003) 1356-1370
4. Barleon B., Reusch P., Totzke F., Herzog C., Keck C., Martiny-Barron G., and Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4 (2001) 143-154
5. Bdolah Y., Sukhatme V.P., and Karumanchi S.A. Angiogenic imbalance in the pathophysiology of pre-eclampsia: newer insights. Semin. Nephrol. 24 6 (2004) 548-556
6. Bdolah Y., Palomaki G.E., Yaron Y., Abram T.B., Goldman M., Levine R.J., Sachs B.P., Haddow J.E., and Karumanchi S.A. Circulating angiogenic proteins in trisomy 13. Am. J. Obstet. Gynecol. 194 (2006) 39-45
7. Bogic L.V., Brace R.A., and Cheung C.Y. Developmental expression of vascular endothelial growth factors (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes. Placenta 22 (2001) 265-275
8. Chaiworapongsa T., Romero R., Espinoza J., Bujold E., Mee K.Y., Goncalves L.F., Gomez R., and Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of pre-eclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190 (2004) 1541-1547
9. Chaiworapongsa T., Romero R., Kim Y.M., Kim G.J., Kim M.R., Espinoza J., Bujold E., Goncalves L., Gomez R., Edwin S., and Mazor M. Plasma soluble VEGFR-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Maternal Fetal Neonatal Med. 17 (2005) 3-18
10. Chaiworapongsa T., Romero R., Gotsch F., Espinoza J., Nien J.K., Goncalves L., Edwin S., Kim Y.M., Erez O., Kusanovic J.P., Pineles B.L., Papp Z., and Hassan S. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in pre-eclampsia and small for gestation age. J. Maternal Fetal Neonatal Med. 21 1 (2008) 41-52
11. Cheung C.Y., and Brace R.A. Developmental receptors of vascular endothelial growth factors and its receptor in ovine placenta and fetal membranes. J. Soc. Gynecol. Invest. 6 (1999) 179-185
12. Clark D.E., Smith S.K., Sharkey A.M., and Harnock Jones D.S. Localisation of VEGF and expression of its receptors Flt and KDR in human placenta throughout pregnancy. Hum. Reprod. 5 (1996) 1090-1098
13. Cooper J.C., Sharkey A.M., McLaren J., Charnock-Jones D.S., and Smith S.K. Localization of vascular endothelial growth factor and its receptor, Flt in human placenta and deciduas by immunohistochemistry. J. Reprod. Fertil. 105 2 (1995) 205-213
14. Demir R., Kayisli U.A., Seval Y., Celik Ozenci C., Korgun E.T., Demir-Weusten A.Y., and Huppertz B. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25 (2004) 560-572
15. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumour angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
16. Erez O., Romero R., Espinoza J., Fu W., Todem D., Kusanovic J.P., Francesca Gotsch, Edwin S., Nien J.K., Chaiworapongsa T., Mittal P., Mazaki-Tovi1 S., Than N.G., Gomez R., and Hassan S.S. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of pre-eclampsia and small-for-gestational age. J. Maternal Fetal Neonatal Med. 21 5 (2008) 279-287
17. Eskes T.K. Abruptio placentae. A "classic" dedicated to Elizabeth Ramsey. Eur. J. Obstet. Gynecol. Reprod. Biol. 75 (1997) 63-70
18. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
19. Geva E., Ginzinger D.G., Zaloudek C.J., Moore D.H., Byrne A., and Jaffe R.B. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1 and angiopoietin-2. J. Clin. Endocrinol. Metab. 87 (2002) 4213-4224
20. Girardi G., Yarilin D., Thurman J.M., Holers V.M., and Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes foetal rejection and growth restriction. J. Exp. Med. 203 (2006) 2165-2175
21. Helske S., Vuorela P., Carpen O., Hornig C., Weich H., and Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol. Hum. Reprod. 7 (2001) 205-210
22. Hinchey J., Chaves C., Appignani B., Breen J., Pao L., Wang A., Pessin M.S., Lamy C., Mas J.L., and Caplan L.R. A reversible posterior leukoencephalopathy syndrome. N. Engl. J. Med. 334 (1996) 494-500
23. Hunter A., Aitkenhead M., Caldwell C., McCracken G., Wilson D., and McClure N. Serum levels of vascular endothelial growth factor in pre-eclamptic and normotensive pregnancy. Hypertension 36 (2000) 965
24. Huppertz B., Kingdom J., Caniggia I., Desoye G., Black S., Korr H., and Kaufmann P. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 24 (2003) 181-190
25. Jaeschke R., Guyatt G., and Sackett D. Users guide to the medical literature III: how to use an article about a diagnostic test. JAMA 271 (1994) 703-707
26. Kearney J.B., Kappas N.C., Ellerstorm C., Dipaola F.W., and Bautch V.L. The VEGF receptor flt-1 is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103 (2004) 4527-4535
27. Kendall R.L., and Thomas K.A. Inhibition of VEGF activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90 (1993) 10705-10709
28. Kim S.Y., Ryu H.M., Yang J.H., Kim M.Y., Han J.Y., and Kim J.O. Increased sFlt-1 to PlGF ratio in women who subsequently develop pre-eclampsia. J. Korean Med. Sci. 22 5 (2007) 873-877
29. Koga K., Osuga Y., Yoshino O., Hirota Y., Ruimeng X., Hirata T., Takeda S., Yano T., Tsutsumi O., Taketani Y., et al. Elevated serum soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) levels in women with pre-eclampsia. J. Clin. Endocrinol. Metab. 88 5 (2003) 2348-2351
30. Levine R.J., Maynard S.E., Qian C., Lim K.H., Lucinda J., Yu K.F., Schisterman E.F., Thadhani R., Sachs B.P., Epstein F.H., Sibai B.M., Sukhatme V.P., and Karumanchi S.A. Circulating angiogenic factors and the risk of pre-eclampsia. N. Engl. J. Med. 350 (2004) 672-683
31. Levine R.J., Lam C., Yu K.F., Maynard S.E., Sachs B.P., Sibai B.M., Epstein F.H., Romero R., Thadhani R., and Karumanchi S.A. Soluble endoglin and other circulating antiangiogenic factors in pre-eclampsia. N. Engl. J. Med. 355 (2006) 992-1005
32. Li H., Gu B., Zhang Y., Lewis D.F., and Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 26 (2005) 210-217
33. Marini M., Vichi D., Toscano A., Zappoli Thyrion G.D., Parretti E., Mello G., Gher G., Pacini A., and Sgambati E. Expression of vascular endothelial growth factor receptor types 1, 2 and 3 in placenta from pregnancies complicated by hypertensive disorders. Reprod. Fertil. Dev. 9 (2007) 641-651
34. Masuyama H., Suwaki N., Nakatsukasa H., Masumoto A., Tateishi Y., and Hiramatrsu Y. Circulating angiogenic factors in pre-eclampsia, gestational proteinuria and pre-eclampsia superimposed on chronic glomerulonephritis. Am. J. Obstet. Gynecol. 194 (2006) 551-556
35. Matsubara K., Nagamatsu T., Fujii T., Kozuma S., and Taketani Y. Lymphokine activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of sFlt-1 from trophoblasts: an implication for the pathophysiology of pre-eclampsia. J. Reprod. Immunol. 68 (2005) 27-37
36. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F., Sukhatme V.P., and Karumanchi S.A. Excess placental soluble Fms-like tyrosine kinase 1(sFlt-1) may contribute to endothelial dysfunction, hypertension and proteinuria in pre-eclampsia. J. Clin. Invest. 111 (2003) 649-658
37. Moore Simas T., Crawford S., Solitro M., Frost S., Meyer B., and Maynard S. Angiogenic factors for the prediction of pre-eclampsia in high-risk women. Am. J. Obst. Gynecol. 197 (2007) 244.e1-244.e8T
38. Munaut C., Lorquet S., Pequeux C., Blacher S., Berndt S., Frankenne F., and Foidart J.M. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum. Reprod. 23 (2008) 1407-1415
39. Nagamatsu T., Fujii T., Kusumi M., Zou L., Yamashita T., Osuga Y., Momoeda M., Kozuma S., and Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinol. 145 (2004) 4838-4845
40. Pandavala S., Pope N., Baker P., and Crocker I. An imbalance between VEGF and its soluble receptor in placental villous explants of intra uterine growth restricted pregnancies. J. Soc. Gynecol. Invest. 13 (2006) 40-47
41. Powers R.W., Roberts J.M., Cooper K.M., Galaher M., Frank M.P., and Harger G.F. Maternal serum soluble Fms like tyrosine kinase-1 concentration are not increased in early pregnancy and decrease more slowly postpartum in women who develop pre-eclampsia. Am. J. Obstet. Gynaecol. 193 (2005) 185-191
42. Rajakumar A., Brandon H.M., Daftary A., Ness R., and Conrad K.P. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in pre-eclamptic placentae. Placenta 25 (2004) 763-769
43. Rajakumar A., Michael H.M., Rajakumar P.A., Shibata E., Hubel C.A., Karumanchi S.A., Thadhani R., Wolf M., Harger G., and Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and pre-eclamptic pregnant women. Placenta 26 (2004) 563-573
44. Rana S., Karumanchi S.A., Levine R.J., Venkatesha S., Rauh-Hain J.A., Tamez H., and Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing pre-eclampsia. Hypertension 50 (2007) 137-142
45. Regnault T.R., Orbus R.J., de Vrijer B., Davidsen M.L., Galan H.L., Wilkening R.B., and Anthony R.V. Placental expression of VEGF, PlGF and their receptors in a model of placental insufficiency-intrauterine growth restriction (PI-IUGR). Placenta 23 (2002) 132-144
46. Roberts J.M., and Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 357 (2001) 53-56
47. Roberts J.M., and Lain K.Y. Recent insight into the pathogenesis of pre-eclampsia. Placenta 23 (2002) 359-372
48. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor and their receptors. J. Cell Sci. 114 (2001) 853-865
49. Rodesch F., Simon P., Donner C., and Jauniaix E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obset. Gynaecol. 80 (1992) 283-285
50. Salahuddin S., Lee Y., Vadnais M., Sachs B.P., and Karumanchi S.A. Diagnostic utility of soluble Fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. AJOG 197 (2007) 28.e1-28.e6
51. Stepan H., Faber R., Wessel N., Wallukat G., Schultheiss H.P., and Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble Fms-like tyrosine kinase 1 in the pathogenesis of pre-eclampsia. J. Clin. Endocrinol. Metab. 91 (2006) 2424-2427
52. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakar A., and Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor-1 induces proteinuria. J. Biol. Chem. 278 (2003) 12605-12608
53. Taylor R.N., Grimwood J., Taylor R.S., McMaster M.T., Fisher S.J., and North R.A. Longitudinal serum concentrations of PLGF: evidence for normal placental angiogenesis in pathogenic pregnancies. Am. J. Obset. Gynaecol. 188 (2003) 177-182
54. Tsatsaris V., Goffin F., Munaut C., Brichant J.F., Pignon M.R., Noel A., Schaaps J.P., Cabrol D., Frankenne F., and Foidart J.M. Over expression of soluble endothelial growth factor receptor in pre-eclamptic patients: patho-physiological consequences. J. Clin. Endocrinol. Metab. 88 (2003) 5555-5563
55. Unal E., Robinson C., Johnson D., and Chang E. Second-trimester angiogenic factors as biomarkers for future-onset pre-eclampsia. Am. J. Obstet. Gynecol. 197 (2007) 0s211.e1-211.e4 E
56. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., and Staff A.C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of pre-eclampsia. Am. J. Obstet. Gynecol. 196 (2007) 239-246
57. Vuckovic M., Ponting J., Terman B.I., Kikelie V., Self M.W., and Kumar S. Expression of VEGF receptor KDR in human placenta. J. Anat. 188 (1996) 361-366
58. Vuorela P., and Halmesmaki E. Vascular endothelial growth factor, its receptors, and the tie receptors in the placental bed of women with pre-eclampsia, diabetes, and intrauterine growth retardation. Am. J. Perinatol. 23 (2006) 255-263
59. Vuorela P., Helske S., Hornig C., Alitalo K., Herbert W., and Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in pre-eclampsia. Obstet. Gynaecol. 95 (2000) 353-357
60. Wathen K.A., Tuutti E., Stenman U.H., Alfthan H., Halmesma E., Finne P., Ylikorkala O., and Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in pre-eclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 91 (2006) 180-184
61. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., and Rosenberg S.A. A randomized trial of an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
62. Yang Gu., Lewis D.F., and Wang Y. Placental productions and expressions of soluble endoglin, soluble Fms-like tyrosine kinase receptor-1, and placental growth factor in normal and pre-eclamptic pregnancies. J. Clin. Endocrinol. Metab. 93 (2008) 260-266
63. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., Alitalo K., Damsky C., and Fisher S.J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelet syndrome. Am. J. Pathol. 160 (2002) 1405-1423